Cocrystal Pharma, Inc. · NASDAQ:COCP
Cocrystal Pharma — Investor Presentation (October 2019)
32 slides from Cocrystal Pharma's investor presentation, Oct 4, 2019
Slide 1: Investor Presentation October 2019
C4 CRYSTAL Investor Presentation PHARMA,INC. October 2019
Slide 2: Forward Looking Statements
A ~ NS Let Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding expected results of our collaboration with Merck Sharp & Dohme Corp. CMe) including the expected acce
Slide 3: Cocrystal's Seasoned Senior Leadership
ms }@ Cocrystal’s Seasoned Senior Leadership xT Gary Wilcox, Ph.D. icOs Cialis XOMA Chairman and Chief Executive Officer + Over 35 years of executive biotech leadership experience and played a key role in the development of Cialis UCLA Sam Lee, Ph.D. President + Over 20 years of anti-infective drug
Slide 4: Corporate Overview
ms ; Lol Corporate Overview Clinical Stage Antiviral Company Influenza Proprietary Drug Hepatitis Discovery Platform Merck Influenza Collaboration Norovirus Gastroenteritis Confidential
Slide 5: Technology and Drug Discovery Platform
mS Lol Technology and Drug Discovery Platform Tec! logy Platform Based on Nobel Prize-winning technology - Near-atomic resolution + X-ray quality crystal production + Drug pocket selection * Hit-to-lead process + Lead optimization EEEEE « Drug candidates Crystal Production Expression & Purification
Slide 6: Robust Development Pipeline
mS Lol Robust Development Pipeline Program Discovery | Preclinical Phase 1 Phase 2a Phase 2b Phase 3 Partner CC-31244 — Hepatitis C (Pan-genotypic NS5B NNI) (HCV) (Pangenetpe nse NN) (Pan-genotypic NS5B NNI) CC-42344 (Influenza A PB2 Inhibitor) Influenza Influenza AJB inhibitor © MERCK Noro Polymera
Slide 7: Merck/Cocrystal Team Initiates Influenza Collaboration
ONS Lol Merck/Cocrystal Team Initiates Influenza Collaboration Received $4 million upfront payment, eligible to receive up to $156 million in milestone payments and royalties (undisclosed) on product sales Exclusive license and collaboration agreement to discover and develop certain proprietary infl
Slide 8: Overview | Antiviral Programs: Hepatitis C
Overview | Antiviral Programs: Hepatitis C
Slide 9: Cocrystal's HCV Strategy
A & }@( Cocrystal’s HCV Strategy ~ a Lead program CC-31244, in ongoing Phase 2a study for the treatment of Hepatitis C Current HCV Market Overview * Clinical limitations of existing long-term HCV therapies: « Longer period for viruses to replicate and mutate, creating significant drug resistance cha
Slide 10: HCV Is Still a Global Issue
A & ; Let HCV Is Still a Global Issue 71 Million 400,000 . 4 people die annually people infected globally fran related causes! Only 20% Only 2% of infected patients of infected patients have been diagnosed! are being treated! 1: Polaris Observatory, 2019 Confidential
Slide 11: Hepatitis C Treatment Market Share
O&® Lol Hepatitis C Treatment Market Share 2017 Annual Sales: $12.69 Billion 2018 Annual Sales: $8.3 Billion J&J AbbVie $1.27B = Gilead (Harvoni, Epclusa, Sovaldi, Vosevi) = Merck (Zepatier) a J&J (Olysio) = AbbVie (Viekira, Mavyret) mAbbVie (Viekira, Mavyret) = Gilead (Harvoni, Epclusa, Sovaldi, Vo
Slide 12: CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor (NNI)
oS ; i Let CC-31244: Broad Spectrum HCV Non-Nucleoside Inhibitor (NNI) Next Wave Combination Therapy HCV GT1 — GT6 NS5B Polymerase Crystals * Potential best-in-class HCV NNI with a strong profile seul ™ I = * Broad spectrum, potent NS5B polymerase inhibitor = ez * High barrier to drug resistance Seo
Slide 13: Potential Best-in-Class NNI
A, ~S Lol Potential Best-in-Class NNI ~ 13 Genotype Dose Treatment Viral Load Reduction e (mg) Frequency (Log,lU/ml) CC-31244 E> Genotypes 1-6 m> 400 => a» (3.0) ABT-333 (Dasabuvir)' Genotype 1 400 BID (1.08) 800 BID (0.95) GS-9190 (Tegobuvir) Genotype 1 40 BID (1.0) 120 BID (1.5) 4. Represents appr
Slide 14: CC-31244: Phase 2a University of Maryland Study Design
ms Lol CC-31244: Phase 2a University of Maryland Study Design Open-label, Phase 2a study evaluating the safety, tolerability and preliminary effi cacy of CC-31244 with approved HCV DAAs (HCV GT1 subjects, N=12) Sofosbuvir and Follow-Up at Velpatasvir 12 & 24 Weeks e———- 4 Weeks ——® CC-31244 (400 mg)
Slide 15: University of Maryland Phase 2a Interim Data
mS Lol University of Maryland Phase 2a Interim Data On January 22, 2019, Cocrystal Pharma announced safety and preliminary efficacy data for its U.S. Phase 2a study evaluating CC-31244 for the ultra-short treatment of HCV infected individuals: All subjects completed the 6-week treatment regimen The
Slide 16: CC-31244: Ongoing Phase 2a Hong Kong Study
Ate Let CC-31244: Ongoing Phase 2a Hong Kong Study Investigator IND; Dr. George Lau, Humanity & Health Research Centre, Hong Kong, China Open-label, safety, tolerability and preliminary efficacy of CC-31244 in combination with sofosbuvir and daclatasvir with or without a protease inhibitor, for the
Slide 17: Overview | Antiviral Programs: Influenza
17 Overview | Antiviral Programs: Influenza
Slide 18: Significant Unmet Need in Growing Influenza Market
ONS Lol Significant Unmet Need in Growing Influenza Market Global influenza market was valued at nearly $5.6 billion in 2017 and is expected to reach nearly $6.5 billion by 2022! Seasonal and pandemic infection 3-5 Million cases of severe illness annually’ 1 Billion Up to 650,000 cases annually? dea
Slide 19: Influenza Remains a Major Global Concern
Fé, NS ; ' Let Influenza Remains a Major Global Concern ting | Vital S Flu season deaths top 80,000 CDC says Ir T S. Edition + last year, September 27, 2018 ~ ~ ~. Ehe New Tork Cimes AARP Flu Deaths On The °°"? | | AAP News 7 . ne 3.2018 This Flu Season Is the Worst in = Rise For Older Americans Nea
Slide 20: Influenza Drug Candidates
os Let Influenza Drug Candidates Influenza A/B Inhibitor Proprietary Influenza A and B Crystals 9 MERCK collaboration ¢ Broad spectrum, potent dual influenza A/B preclinical lead will be developed « Results of Cocrystal’s drug discovery platform technology * Binds to highly conserved site of influen
Slide 21: Influenza Drug Candidates
oS 1S Influenza Drug Candidates ~F Antiviral Product Candidates Target All Strains of the Influenza A Virus Influenza A Inhibitor CEN Influenza PB2 Crystals ° Binds to the highly conserved m7GTP binding pocket of PB2 ¢ Exhibits broad spectrum activity against seasonal and pandemic influenza strains,
Slide 22: CC-42344 Shows Strong Synergistic Effects With Approved Influenza Antivirals
Lr CC-42344 Shows Strong Synergistic Effects With Approved es Influenza Antivirals Polymerase Inhibitor Favipiravir Cocrystal 42344 PA Inhibitor Neuraminidase Inhibitor Confidential
Slide 23: CC-42344: Pharmacological, Safety, Toxicity, and PK Evaluations
ms rot CC-42344: Pharmacological, Safety, Toxicity, and PK Evaluations Cc xT S6B68 SBSBGE6E6B8B6B6B6868B8 ompleted To Date In vitro antiviral profiling against seasonal and pandemic influenza A strains Cytotoxicity including larger screen: HepG2/high content analysis and 13 cell lines Caco-2 bidirec
Slide 24: Overview | Antiviral Programs: Norovirus
24 Overview | Antiviral Programs: Norovirus
Slide 25: Norovirus Is an Area of Significant Unmet Need
A Nw 1S Norovirus Is an Area of Significant Unmet Need Norovirus Market Overview Known Causes of Foodborne Illness Outbreaks, U.S.2 ¢ No approved antiviral drugs for the treatment of Noro infection Parasites 1% ; $4.2 billion in direct health system costs! ree bases 4 700 million 19-21 million 4% Ch
Slide 26: Cocrystal's Norovirus Program
mS Lol Cocrystal’s Norovirus Program Norovirus Polymerase NNI Lead Development Ongoing Noro Polymerase NNIs |_Norovirue Polymerase NNI Lead Development Ongoing | Norovirus and Norwalk Polymerase Crystals Potential first-in-class NNI Potent and broad spectrum anti-Noro polymerase inhibitors Toolbox c
Slide 27: Intellectual Property
AN 1@{ Intellectual Property Patents and pending applications in the areas primarily related to the treatment of HCV, influenza A and influenza A/B * HCV Treatment * NSS5B (non-nucleoside inhibitor) * Issued patents in U.S. * Pending applications in U.S., Australia, Brazil, Canada, China, Europe, Eu
Slide 28: Well-Positioned for Growth
28 Well-Positioned for Growth
Slide 29: Financial Snapshot
ror Financial Snapshot: NASDAQ: COCP xT 31.6MM ~5.4K Common shares Average daily outstanding volume’ : Common Shares Outstanding (Directors, Officers and ~$64M Market cap Affiliates) 15,214,178 46.39% Common Shares Outstanding (Other) 16,406,468 50.03% Warrants 243,375 $10.53 $2,562,739 0.74% Stock
Slide 30: Strategy Directed at Advancing Programs and Growing Value
ONS Lol Strategy Directed at Advancing Programs and Growing Value ¢ Growth in focused therapeutic areas ¢ Continue to build an innovative pipeline ¢ Form additional strategic collaborations and partnerships ¢ Ongoing collaboration with Merck expected to accelerate influenza drug development program
Slide 31: Upcoming Milestones Expected to Drive Value
ms Lol Upcoming Milestones Expected to Drive Value Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q3 2021 Influenza A/B Hepatitis C Influenza A Influenza Hepatitis C Influenza A Noro. Platform Influenza A Merck A/B Merck Collaboration Phase 2a USA — Interim Results Phase 2a (Hong Ko
Slide 32: Thank you!
CHC RYSTA L Thank you! Pages ReM AG, | N
Cocrystal Pharma — Investor Presentation (October 2019) on 6ix